Literature DB >> 31420805

Kinins in Glioblastoma Microenvironment.

Mona N Oliveira1,2, Barbara Breznik3, Micheli M Pillat1, Ricardo L Pereira1, Henning Ulrich1, Tamara T Lah4,5.   

Abstract

Tumour progression involves interactions among various cancer cell clones, including the cancer stem cell subpopulation and exogenous cellular components, termed cancer stromal cells. The latter include a plethora of tumour infiltrating immunocompetent cells, among which are also immuno-modulatory mesenchymal stem cells, which by vigorous migration to growing tumours and susequent transdifferentiation into various types of tumour-residing stromal cells, may either inhibit or support tumour progression. In the light of the scarce therapeutic options existing for the most malignant brain tumour glioblastoma, mesenchymal stem cells may represent a promising novel tool for cell therapy, e.g. drug delivery vectors. Here, we review the increasing number of reports on mutual interactions between mesenchymal stem cells and glioblastoma cells in their microenvironment. We particularly point out two novel aspects: the different responses of cancer cells to their microenvironmental cues, and to the signalling by kinin receptors that complement the immuno-modulating cytokine-signalling networks. Inflammatory glioblastoma microenvironment is characterised by increasing expression of kinin receptors during progressive glioma malignancy, thus making kinin signalling and kinins themselves rather important in this context. In general, their role in tumour microenvironment has not been explored so far. In addition, kinins also regulate blood brain barrier-related drug transfer as well as brain tumour angiogenesis. These studies support the on-going research on kinin antagonists as candidates in the development of anti-invasive agents for adjuvant glioblastoma therapy.

Entities:  

Keywords:  Co-culture; Glioma; Kinin receptors; Mesenchymal stem cells; Microenvironment; Tumour heterogeneity

Year:  2019        PMID: 31420805      PMCID: PMC6937362          DOI: 10.1007/s12307-019-00229-x

Source DB:  PubMed          Journal:  Cancer Microenviron        ISSN: 1875-2284


  134 in total

1.  Kinin-B1 and B2 receptors and neural differentiation of pluripotent or multipotent stem cells.

Authors:  Yang D Teng
Journal:  Cytometry A       Date:  2015-08-04       Impact factor: 4.355

2.  Vesicle transfer and cell fusion: Emerging concepts of cell-cell communication in the tumor microenvironment.

Authors:  T Kevin Howcroft; Huang-Ge Zhang; Madhav Dhodapkar; Suresh Mohla
Journal:  Cancer Biol Ther       Date:  2011-08-01       Impact factor: 4.742

3.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.

Authors:  Shideng Bao; Qiulian Wu; Roger E McLendon; Yueling Hao; Qing Shi; Anita B Hjelmeland; Mark W Dewhirst; Darell D Bigner; Jeremy N Rich
Journal:  Nature       Date:  2006-10-18       Impact factor: 49.962

4.  Upregulation of PTEN in glioma cells by cord blood mesenchymal stem cells inhibits migration via downregulation of the PI3K/Akt pathway.

Authors:  Venkata Ramesh Dasari; Kiranpreet Kaur; Kiran Kumar Velpula; Meena Gujrati; Daniel Fassett; Jeffrey D Klopfenstein; Dzung H Dinh; Jasti S Rao
Journal:  PLoS One       Date:  2010-04-26       Impact factor: 3.240

Review 5.  Stem cell-based therapies for cancer treatment: separating hope from hype.

Authors:  Daniel W Stuckey; Khalid Shah
Journal:  Nat Rev Cancer       Date:  2014-09-01       Impact factor: 60.716

6.  Glioblastoma-mesenchymal stem cell communication modulates expression patterns of kinin receptors: Possible involvement of bradykinin in information flow.

Authors:  Micheli M Pillat; Mona N Oliveira; Helena Motaln; Barbara Breznik; Talita Glaser; Tamara T Lah; Henning Ulrich
Journal:  Cytometry A       Date:  2015-12-15       Impact factor: 4.355

Review 7.  Tissue Regeneration in the Chronically Inflamed Tumor Environment: Implications for Cell Fusion Driven Tumor Progression and Therapy Resistant Tumor Hybrid Cells.

Authors:  Thomas Dittmar; Kurt S Zänker
Journal:  Int J Mol Sci       Date:  2015-12-19       Impact factor: 5.923

8.  Mitosis can drive cell cannibalism through entosis.

Authors:  Joanne Durgan; Yun-Yu Tseng; Jens C Hamann; Marie-Charlotte Domart; Lucy Collinson; Alan Hall; Michael Overholtzer; Oliver Florey
Journal:  Elife       Date:  2017-07-11       Impact factor: 8.140

9.  Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers.

Authors:  Johan Skog; Tom Würdinger; Sjoerd van Rijn; Dimphna H Meijer; Laura Gainche; Miguel Sena-Esteves; William T Curry; Bob S Carter; Anna M Krichevsky; Xandra O Breakefield
Journal:  Nat Cell Biol       Date:  2008-11-16       Impact factor: 28.824

10.  Spontaneous cancer-stromal cell fusion as a mechanism of prostate cancer androgen-independent progression.

Authors:  Ruoxiang Wang; Xiaojuan Sun; Christopher Y Wang; Peizhen Hu; Chia-Yi Chu; Shurong Liu; Haiyen E Zhau; Leland W K Chung
Journal:  PLoS One       Date:  2012-08-03       Impact factor: 3.240

View more
  3 in total

1.  CCR5 as a Prognostic Factor in Lower-Grade Glioma is Involved in the Remodeling of the Tumor Microenvironment.

Authors:  Fang Wang; Zhennan Tao; Zhen Tian; Jiaqi Jin; Jiawei Dong; Yuxiang Dai; Wanli Yu; Bin Tang; Shaoshan Hu
Journal:  Front Genet       Date:  2022-07-05       Impact factor: 4.772

2.  Anti-MicroRNA-21 Oligonucleotide Loaded Spermine-Modified Acetalated Dextran Nanoparticles for B1 Receptor-Targeted Gene Therapy and Antiangiogenesis Therapy.

Authors:  Tao Zheng; Wentao Wang; Mohsen Mohammadniaei; Jon Ashley; Ming Zhang; Ninglin Zhou; Jian Shen; Yi Sun
Journal:  Adv Sci (Weinh)       Date:  2021-12-22       Impact factor: 16.806

3.  CCR5-Mediated Signaling Is Involved in Invasion of Glioblastoma Cells in Its Microenvironment.

Authors:  Metka Novak; Miha Koprivnikar Krajnc; Barbara Hrastar; Barbara Breznik; Bernarda Majc; Mateja Mlinar; Ana Rotter; Andrej Porčnik; Jernej Mlakar; Katja Stare; Richard G Pestell; Tamara Lah Turnšek
Journal:  Int J Mol Sci       Date:  2020-06-12       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.